Improving the use of anticoagulant therapies in acutely ill medical patients

American Journal of Health-System Pharmacy

Volumn 65, Issue 15 SUPPL. 7, 2008, Pages

  Dobesh, Paul P ^a,e   Phillips, Katherine W ^b   Haines, Stuart T ^c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Drugs; Enoxaparin; Heparin; Hospitals; Mortality; Pharmacists; Pharmacoeconomics; Prescribing; Rational therapy; Toxicity; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CAPILLARY RESISTANCE; CASE REPORT; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; EDUCATION PROGRAM; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HEMATOMA; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LUNG EMBOLISM; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 49449098377     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080240     Document Type: Conference Paper

References (40)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
2. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115:e69-171.
3. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):338S-400S.
4. Keane MG, Ingenito EP, Goldhaber SZ. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest. 1994;106:13-4.
5. Stinnett JM, Pendleton R, Skordos L et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol. 2005;78:167-72.
6. Deitelzweig S; Groce JB 3rd; Heparin Consensus Group. Anticoagulant prophylaxis in medical patients: an objective assessment. Pharmacotherapy. 2004; 24(8 Pt 2):120S-126S.
7. Yu HT, Dylan ML, Lin J et al. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health-Syst Pharm. 2007; 64:69-76.
8. Francis CW Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007; 356:1438-44.
9. The Joint Commission. National consensus standards for prevention and care of venous thromboembolism (VTE). www.jointcommission.org/ PerformanceMeasurement/ PerformanceMeasurement/VTE.htm (accessed 2008 Jan 9).
10. Nutescu EA. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches. Am J Health-Syst Pharm. 2007; 64(Suppl7):S5-13.
11. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51:70-8.
12. Lutz L, Haas S, Hach-Wunderle V et al. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis: publication for the specialist platform. Med Welt. 2002; 53:231-4.
13. Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003; 14:341-6.
14. Samama MM, Cohen AT, Darmon JY et al. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800.
15. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004; 93:259-62.
16. Tapson VF, Decousus H, Pini M et al.; the IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. Findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007; 132:936-45.
17. Enders JM, Burke JM, Dobesh PP. Prevention of venous thromboembolism in acute medical illness. Pharmacotherapy. 2002; 22:1564-78.
18. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb. 2002; 28:577-84.
19. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate N et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988;39:505-13.
20. Halkin H, Goldberg J, Modan M et al. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med. 1982; 96:561-5.
21. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982; 10:448-50.
22. Gärdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996; 347:1357-61.
23. Glagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg. 1988; 208:227-40.
24. Clarke-Pearson DL, Coleman RE, Synan IS et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol. 1983; 145:606-13.
25. Clark-Pearson DL, DeLong E, Synan IS et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol. 1990; 75:684-9.
26. Belch JJ, Lowe GD, Ward AG et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981; 26:115-7.
27. Gallus AS, Hirsh J, Tuttle RJ et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med. 1973; 288:545-51.
28. King CS, Holley AB, Jackson JL et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A meta-analysis. Chest. 2007;131:507-16.
29. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110:874-9.
30. Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006; 332:325-9.
31. Dentali F, Douketis JD, Gianni M et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007; 146:278-88.
32. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996; 26(Suppl 2):49-56.
33. Kleber FX, Witt C, Vogel G et al.; THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003; 145:614-21.
34. Harenberg J, Schomaker U, Flosbach CW. Enoxaparin is superior to unfractionated heparin in the prevention of venous thromboembolic events in medical patients at increased thromboembolic risk. Blood. 1999; 94(Suppl 1):399a. Abstract.
35. Hillborn M, Erila T, Sotaniemi K et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand. 2002; 106:84-92.
36. Dobesh PP, Stacy ZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm. 2005; 11:755-62.
37. Tooher R, Middleton P, Pham C et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005; 241:397-415.
38. The Joint Commission. 2008 national patient safety goals: critical access hospital program. www.jointcommission.org/NR/rdonlyres/0B4EB2A3-0AD5-4B9B-B891- D2BCE33D8D49/0/08_CAH_NPSGs_Master.pdf (accessed 2008 Jan 7).
39. Dager WE, Branch JM, King JH et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist -managed anticoagulation service. Ann Pharmacother. 2000; 34:567-72.
40. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004; 24:953-63.